Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
Orthocell (ASX:OCC) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 69,327 shares. Over the past 30 days that figure has fallen 0.24 percentage points, and over 90 days it has fallen 0.34 percentage points. Its highest recorded short interest was 0.94% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Orthocell (OCC) short interest history
OCC Short Interest History
- 30-day change
- -0.24pp
- 90-day change
- -0.34pp
- 1-year change
- +0.01pp
- All-time high
- 0.94% (December 2025)
- All-time low
- 0.00% (January 2025)
Is OCC heavily shorted?
Not especially: 0.03% short interest is modest by ASX standards, ranking #543 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has OCC's short interest changed recently?
Over the past 30 days Orthocell's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.03% of shares on issue.
What is the highest OCC's short interest has been?
Since 2015, Orthocell's short interest peaked at 0.94% in December 2025 and bottomed at 0.00% in January 2025.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2015. See our methodology.